<?xml version="1.0" encoding="UTF-8"?>
<p>The development of ART medications for HIV over the last two decades has transformed treatment for HIV, from an acute, palliative focus, to a long-term, managed effort. According to the current guidelines, all HIV positive persons should be started on ART regimen regardless of their CD4 counts [
 <xref rid="B13-pharmacy-08-00108" ref-type="bibr">13</xref>]. The rationale for this recommendation is to decrease mortality and morbidity associated with HIV infection, and reduce transmission [
 <xref rid="B13-pharmacy-08-00108" ref-type="bibr">13</xref>]. Commonly, an initial regimen consists of three ART medications, that belong to at least two different classes [
 <xref rid="B13-pharmacy-08-00108" ref-type="bibr">13</xref>]. This is changing with the introduction of two drug combinations, with more in development [
 <xref rid="B14-pharmacy-08-00108" ref-type="bibr">14</xref>]. 
</p>
